mexiletine has been researched along with Syncope in 8 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
Syncope: A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Erythromycin is a selective IKr-blocking, action potential duration (APD)-prolonging drug, which may induce early afterdepolarizations (EADs) and torsade de pointes ventricular tachycardia." | 7.70 | Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine. ( Fazekas, T; Krassói, I; Lengyel, C; Papp, JG; Varró, A, 1998) |
| "Significant differences between pre- and posttreatment number of VPC, severity of arrhythmia, HR variables, or occurrence of syncope were not observed in dogs treated with atenolol or procainamide." | 5.10 | Comparison of the effects of four antiarrhythmic treatments for familial ventricular arrhythmias in Boxers. ( Atkins, CE; DeFrancesco, TC; Gordon, SG; Hamlin, RL; Keene, BW; Meurs, KM; Miller, MW; Moise, NS; Spier, AW; Wright, NA, 2002) |
| "Erythromycin is a selective IKr-blocking, action potential duration (APD)-prolonging drug, which may induce early afterdepolarizations (EADs) and torsade de pointes ventricular tachycardia." | 3.70 | Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine. ( Fazekas, T; Krassói, I; Lengyel, C; Papp, JG; Varró, A, 1998) |
| "In 5 Mexiletine was added, shortening QTc and obtaining the disappearance of the T-wave alternance (TWA) in 3/3." | 1.91 | Autosomal Recessive Long QT Syndrome: Clinical Aspects and Therapy. ( Baban, A; Di Mambro, C; Drago, F; Gnazzo, M; Novelli, A; Paglia, S; Porco, L; Righi, D; Silvetti, MS; Tozzi, AE, 2023) |
| "Mexiletine is a Class 1B antiarrhythmic drug that causes the disappearance of T-wave alternans by shortening QTc and peak-to-end of the T wave." | 1.48 | A case report: Is mexiletine usage effective in the shortening of QTC interval and improving the T-wave alternans in Timothy syndrome? ( Ergul, Y; Tunca Sahin, G, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Righi, D | 1 |
| Porco, L | 1 |
| Di Mambro, C | 1 |
| Gnazzo, M | 1 |
| Baban, A | 1 |
| Paglia, S | 1 |
| Silvetti, MS | 1 |
| Novelli, A | 1 |
| Tozzi, AE | 1 |
| Drago, F | 1 |
| Tunca Sahin, G | 1 |
| Ergul, Y | 1 |
| Park, J | 1 |
| Kim, SK | 1 |
| Pak, HN | 1 |
| Meurs, KM | 1 |
| Spier, AW | 1 |
| Wright, NA | 1 |
| Atkins, CE | 1 |
| DeFrancesco, TC | 1 |
| Gordon, SG | 1 |
| Hamlin, RL | 1 |
| Keene, BW | 1 |
| Miller, MW | 1 |
| Moise, NS | 1 |
| Priori, SG | 1 |
| Napolitano, C | 1 |
| Paganini, V | 1 |
| Cantù, F | 1 |
| Schwartz, PJ | 1 |
| Hirata, K | 1 |
| Takagi, Y | 1 |
| Nakada, M | 1 |
| Kyushima, M | 1 |
| Asato, H | 1 |
| Fazekas, T | 1 |
| Krassói, I | 1 |
| Lengyel, C | 1 |
| Varró, A | 1 |
| Papp, JG | 1 |
| Rosenheck, S | 1 |
| Schmaltz, S | 1 |
| Kadish, AH | 1 |
| Summitt, J | 1 |
| Morady, F | 1 |
1 review available for mexiletine and Syncope
| Article | Year |
|---|---|
Molecular biology of the long QT syndrome: impact on management.
Topics: Action Potentials; Adrenergic Antagonists; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artifici | 1997 |
1 trial available for mexiletine and Syncope
| Article | Year |
|---|---|
Comparison of the effects of four antiarrhythmic treatments for familial ventricular arrhythmias in Boxers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Dog Diseases; Dogs; Drug Therapy, C | 2002 |
6 other studies available for mexiletine and Syncope
| Article | Year |
|---|---|
Autosomal Recessive Long QT Syndrome: Clinical Aspects and Therapy.
Topics: Child; Deafness; Heart Arrest; Humans; Jervell-Lange Nielsen Syndrome; KCNQ1 Potassium Channel; Long | 2023 |
A case report: Is mexiletine usage effective in the shortening of QTC interval and improving the T-wave alternans in Timothy syndrome?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autistic Disorder; Child, Preschool; Electrocardiograp | 2018 |
A case of Long QT syndrome type 3 aggravated by beta-blockers and alleviated by mexiletine: the role of epinephrine provocation test.
Topics: Adolescent; Adrenergic beta-Antagonists; Defibrillators, Implantable; Diagnosis, Differential; Diagn | 2013 |
Beat-to-beat variation of the ST segment in a patient with right bundle branch block, persistent ST segment elevation, and ventricular fibrillation: a case report.
Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Electric Countershock; Electrocardiography; Hear | 1998 |
Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Dogs; Electric Stimulatio | 1998 |
The effect of quinidine and mexiletine on the adaptation of ventricular refractoriness to an increase in rate.
Topics: Adaptation, Physiological; Adult; Aged; Drug Evaluation; Electrophysiology; Female; Heart; Heart Rat | 1991 |